Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   


types of dementia2 - risk factors1 - risk for alzheimer's1 - high cholesterol1 - amyloid markers1 - vascular dementia warning signs1 - amyloid-beta4 - imbecility1 - physical activity2 - aggression or irritability1 - cognitive tests1 - alzheimers society2 - parkinson's treatment1 - alzheimer's-like tau tangles1 - alzheimer's treatment3 - emotional symptoms1 - physical reality1 - neurodegenerative diseases1 - physical weakness1 - kraepelin3 - parkinson's psychosis1 - emission computed tomography1 - beta-blocker drugs1 - spread of alzheimers1 - poor sleep1 - alzheimers disease25 - parkinson's dementia1 - cardiac arrest1 - olanzapine1 - dopamine6 -